Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for IVVD, RVYL and HMC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Tuesday, 07 February 2023 09:30 AM

Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / February 7, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

IVVD Shareholders Click Here: https://www.zlk.com/pslra-1/invivyd-loss-submission-form?prid=36309&wire=1
RVYL Shareholders Click Here: https://www.zlk.com/pslra-1/ryvyl-inc-loss-submission-form?prid=36309&wire=1
HMC Shareholders Click Here: https://www.zlk.com/pslra-1/honda-lawsuit-loss-submission-form?prid=36309&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Tuesday, February 7, 2023, Press release picture

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ:IVVD)

This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.
Lead Plaintiff Deadline : April 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/invivyd-loss-submission-form?prid=36309&wire=1

According to the filed complaint, (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

Ryvyl Inc. f/k/a GreenBox POS (NASDAQ:RVYL)

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Ryvyl securities: (1) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's January 29, 2021 public offering; and/or (2) between January 29, 2021 and January 20, 2023, inclusive.
Lead Plaintiff Deadline : April 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ryvyl-inc-loss-submission-form?prid=36309&wire=1

According to the filed complaint, (1) Ryvyl downplayed serious issues with its internal controls; (2) Ryvyl's financial statements for December 31, 2021 through and including interim periods ended September 30, June 30, and March 31, 2022 contained errors resulting in overstatements of revenue, assets, and stockholders' equity and understatements of losses; (3) as a result, Ryvyl would need to restate its previously issued financial statements for those periods; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Honda Motor Co., Ltd. (NYSE:HMC)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired Honda American Depository Shares between June 20, 2018 and September 28, 2022, both dates inclusive.
Lead Plaintiff Deadline : April 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/honda-lawsuit-loss-submission-form?prid=36309&wire=1

According to the filed complaint, (i) Honda had overstated the safety and effectiveness of the Idle Stop engine feature; (ii) Honda maintained deficient disclosure controls and procedures with respect to product quality and safety; (iii) as a result of the foregoing deficiencies, Honda failed to prevent American Honda from marketing and selling thousands of vehicles that contained a defective Idle Stop feature; (iv) the foregoing conduct subjected the Company and/or its subsidiaries to a heightened risk of litigation, as well as financial and/or reputational harm; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Class Action
Back to newsroom
Back to Newsroom
Share by: